Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

Trial Profile

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs MCLA 128 (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Merus
  • Most Recent Events

    • 27 Dec 2018 According to a Merus media release, the company plans to provide an update on this study in the second half of 2019.
    • 26 Jan 2018 According to a Merus media release, first patient has been dosed in the trial.
    • 26 Jan 2018 Status changed from not yet recruiting to recruiting, according to a Merus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top